TELA Bio (TELA) Net Cash Flow Growth (3y) (2021 - 2026)
TELA Bio (TELA) Net Cash Flow Growth (3y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 182.30 Bn | 175.00 Bn | 6.27 Bn | -32.51% |
| 2 | Stryker | 128.77 Bn | 125.89 Bn | 3.81 Bn | -87.87% |
| 3 | Medtronic | 107.99 Bn | 98.77 Bn | 6.41 Bn | 31.32% |
| 4 | Boston Scientific | 67.85 Bn | 66.39 Bn | 3.61 Bn | -11.49% |
| 5 | Edwards Lifesciences | 48.12 Bn | 44.45 Bn | 1.29 Bn | -87.88% |
| 6 | Dexcom | 28.26 Bn | 27.14 Bn | 750.30 Mn | 129.29% |
| 7 | GE HealthCare Technologies | 27.98 Bn | 25.70 Bn | 1.98 Bn | -65.12% |
| 8 | Smith & Nephew | 26.99 Bn | 26.41 Bn | - | - |
| 9 | Koninklijke Philips | 23.78 Bn | 20.65 Bn | 2.07 Bn | -48.90% |
| 10 | TELA Bio | 38.25 Mn | -1.29 Mn | 12.52 Mn | 1.84% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.84% |
| Dec 31, 2025 | 55.06% |
| Sep 30, 2025 | -30.10% |
| Jun 30, 2025 | -13.72% |
| Mar 31, 2025 | 3.84% |
| Dec 31, 2024 | 77.86% |
| Sep 30, 2024 | -10.58% |
| Jun 30, 2024 | -24.30% |
| Mar 31, 2024 | -3.97% |
| Dec 31, 2023 | -16.51% |
| Sep 30, 2023 | -20.66% |
| Jun 30, 2023 | -7.40% |
| Mar 31, 2023 | -45.28% |
| Dec 31, 2022 | -33.02% |
| Sep 30, 2022 | 92.65% |
| Jun 30, 2022 | -41.18% |
| Mar 31, 2022 | -11.65% |
| Dec 31, 2021 | -38.06% |